PT-141 vs Viagra: how the two arousal drugs actually differ

Last updated 2026-07-25

What is the core difference between PT-141 and Viagra?

PT-141 and Viagra get lumped together because both get marketed around sex, but they don't do the same job and they don't work in the same place in the body. Viagra (sildenafil) is a PDE5 inhibitor. It blocks an enzyme in blood vessel walls, which lets nitric oxide relax smooth muscle and increase blood flow into the penis. That's a local, vascular effect. It doesn't touch desire. A man can take sildenafil and still feel zero interest in sex; the drug just makes an erection easier to get and keep once he's aroused. Bremelanotide (the generic name for PT-141, sold as Vyleesi) is a melanocortin receptor agonist. It acts in the brain, specifically on MC4R pathways tied to sexual motivation, not on genital blood vessels ^[1][2]. It's FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, a condition defined by low desire that causes personal distress, not a circulation problem ^[3]. So the one-line version: Viagra treats erectile function, a mechanical and vascular problem. PT-141 treats desire, a central nervous system signal. Different organs, different receptors, different approved patient populations. For background on the receptor biology itself, see our pt 141 peptide overview.

How does PT-141 work in the brain versus how Viagra works on blood flow?

The mechanism split is the single most useful thing to understand before comparing anything else about these two drugs. Bremelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone. It binds melanocortin 4 receptors (MC4R) in the hypothalamus and other central sites tied to sexual response and appetite regulation ^[4]. Research on the melanocortin system shows these receptors sit upstream of motivation and arousal circuits, and MC4R agonism has been studied for effects well beyond sex, including body weight regulation ^[4][5]. One phase 1 dataset in obese women found measurable body weight effects with bremelanotide dosing, which tells you this receptor system reaches metabolic pathways, more than sexual ones ^[5]. Sildenafil never enters that conversation. It's confined to the nitric oxide/cGMP pathway in vascular smooth muscle. It inhibits phosphodiesterase type 5, the enzyme that breaks down cGMP, so cGMP accumulates, vessels relax, and blood pools in the corpus cavernosum. That's why sildenafil needs sexual stimulation to work at all: no arousal signal, no nitric oxide release, no effect. PT-141's central mechanism doesn't have that same stimulation-dependency in the same way, because it's acting on the desire signal itself rather than amplifying a vascular response to stimulation already occurring. A 2022 review in CNS Spectrums lays out this neurobiology specifically for bremelanotide in premenopausal women with HSDD, describing the drug's action on central melanocortin pathways as distinct from peripheral vasoactive drugs used in male ED ^[2]. That's the citation to point to if you want the mechanism distinction in one place.

Is PT-141 FDA-approved the same way Viagra is?

Both drugs are FDA-approved, but for different conditions in different populations, and that matters for anyone comparing them as if they're substitutes. Bremelanotide was approved by the FDA in 2019 under the brand name Vyleesi, specifically for acquired, generalized HSDD in premenopausal women ^[3][6]. "Acquired" means desire that used to be normal and dropped; "generalized" means it's not limited to one partner or situation. It's an on-demand subcutaneous injection, not a daily pill. Sildenafil was approved by the FDA in 1998 for erectile dysfunction in men (Drugs@FDA lists the original Viagra approval and all subsequent generics) ^[7]. It's an oral tablet taken roughly 30 to 60 minutes before anticipated sexual activity. Neither drug is approved for the other's population. Sildenafil is not FDA-approved for female desire disorders. Bremelanotide is not approved for male erectile dysfunction, though the melanocortin system itself has been studied in male sexual dysfunction research going back to earlier work in the 2000s ^[8][9]. If you see PT-141 marketed to men for erections specifically, that's off-label, unapproved territory, not what the Vyleesi trials tested. A 2021 commentary in Drug and Therapeutics Bulletin pushed back on drawing regulatory comparisons between bremelanotide, flibanserin, and existing approved drugs, arguing the precedent logic used to support approval doesn't hold up well under scrutiny ^[10]. Worth reading if you want the skeptical side of the approval story.

How well does PT-141 actually work compared to Viagra's effect on ED?

The two drugs get judged on completely different endpoints, so a head-to-head efficacy number doesn't really exist. Here's what the trial data actually shows for each. The core bremelanotide trials (RECONNECT, two phase 3 randomized studies) measured change in Female Sexual Function Index desire domain score and a distress measure called FSDS-DAO, not orgasm rate or an intercourse count ^[11]. Across the two trials, bremelanotide produced statistically significant improvement over placebo on desire score, though the absolute difference was modest. A 2019 responder analysis from an earlier phase 2b dose-ranging study found meaningful but variable response rates depending on dose tested ^[12]. A more critical 2024 paper in the Journal of Sex Research, titled directly "Small Effects, Questionable Outcomes," re-examined the phase 3 data and argued the clinically meaningful difference over placebo is small when you look at raw score change rather than statistical significance alone ^[13]. A separate 2021 re-analysis in the same journal raised similar concerns about how HSDD outcomes were defined and measured in the original trials ^[14]. This isn't fringe criticism; it's published, peer-reviewed pushback that any honest comparison needs to mention. Sildenafil's efficacy data is a different animal entirely: it's measured by erection hardness scores and successful intercourse attempts, and the effect size in men with organic ED is generally described as larger and more consistent than what's reported for bremelanotide's desire endpoint, though these aren't directly comparable trials measuring the same thing. Bottom line: sildenafil has a longer track record (approved since 1998) and a mechanical, more immediately measurable effect. Bremelanotide's effect is real but modest, and reasonable researchers disagree about how clinically meaningful the average improvement is ^[13][14].

What side effects does PT-141 cause that Viagra doesn't?

This is where the two drugs diverge sharply, and honesty here matters more than marketing copy. Nausea is the standout side effect of bremelanotide. Across the clinical development program, nausea was reported in a large share of patients, commonly cited around 40% in the phase 3 trials, and it's dose-related and usually worse on the first dose ^[11][15]. Flushing is the second most common effect, along with injection site reactions since Vyleesi is a subcutaneous injection ^[15]. A transient rise in blood pressure and drop in heart rate can also occur in the hours after dosing, which is why the label advises against use in people with uncontrolled hypertension or known cardiovascular disease ^[16]. A 2022 safety review pooling data across the full bremelanotide development program confirmed nausea, flushing, and headache as the most frequent adverse events, with nausea severity generally decreasing after the first one or two doses in repeat users ^[15]. Sildenafil's side effect profile looks different because the mechanism is different: headache, flushing, nasal congestion, visual disturbances (a bluish tinge to vision), and indigestion are typical, all tied to systemic vasodilation. Nausea is not a hallmark sildenafil side effect the way it is for bremelanotide. Serious cardiovascular caution applies to sildenafil too, especially the absolute contraindication against combining it with nitrate medications, which can cause dangerous hypotension. Neither side effect list is trivial. If nausea after a subcutaneous injection sounds unacceptable to you, that's a legitimate reason to think hard before starting bremelanotide, and it's worth reading our PT-141 dosage page for how dose timing affects how rough that first dose actually feels.

Can men use PT-141, or is it only for women?

Vyleesi's FDA approval covers only premenopausal women with acquired, generalized HSDD ^[3][6]. There is no FDA-approved bremelanotide product for men. That said, the melanocortin receptor system isn't sex-specific biology, and older research going back to the mid-2000s looked at bremelanotide (then studied under earlier development names) for male erectile dysfunction, including in men who didn't respond well to PDE5 inhibitors ^[9]. A 2006 paper specifically discussed bremelanotide as a potential option positioned somewhat like a "female Viagra" concept, reflecting how early development framed the drug relative to sildenafil ^[17]. None of that research led to an approved male indication in the US. Compounded PT-141 marketed to men today sits outside FDA-approved use. It typically comes from compounding pharmacies rather than as an FDA-approved finished product, which means it hasn't gone through the same phase 3 efficacy and safety review that Vyleesi did for women. Bulk bremelanotide sourcing for compounding is governed by FDA's 503A and 503B bulk substance rules ^[18][19], and the substance's regulatory status there is a separate question from whether a compounded product is safe or effective for any particular use in men. Anyone considering it off-label should know that distinction going in.

Can PT-141 and Viagra be used together?

There's no FDA-approved combination protocol, and the trials that got Vyleesi approved didn't test it stacked with a PDE5 inhibitor as standard practice. Because the two drugs work through completely separate pathways (central desire signaling versus peripheral vascular relaxation), there's no obvious pharmacological conflict in the way there is between sildenafil and nitrates, but that's a mechanistic argument, not a safety guarantee backed by combination trial data. Because bremelanotide can transiently raise blood pressure and lower heart rate, and PDE5 inhibitors lower blood pressure through vasodilation, stacking them without medical supervision is not something to improvise. If you're on both for legitimate separate indications (say, a man with ED on sildenafil whose partner has HSDD and is on Vyleesi), that's two people on two different drugs, not one person combining them, which is actually the more common real-world scenario. Anyone actually taking both drugs personally should run it by the prescriber who wrote both, not a forum thread.

How is PT-141 dosed compared to Viagra?

The dosing schedules look nothing alike, and that's another practical difference worth knowing before you decide anything. Vyleesi comes as a pre-filled autoinjector delivering 1.75 mg subcutaneously, self-injected in the thigh or abdomen at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than 8 doses per month per the product's studied regimen ^[6]. It's on-demand, not daily. Sildenafil for ED is typically taken as a single oral tablet (commonly 25, 50, or 100 mg) roughly 30 to 60 minutes before sexual activity, also on an as-needed basis, generally not more than once daily. Neither drug is meant for daily continuous dosing the way, say, a blood pressure medication is. Both are event-dosed. For the specifics of injection technique and rotating sites, see PT-141 how to inject and PT-141 injection sites. If you're wondering how a monthly dosing pattern is supposed to look over time, PT-141 cycle length covers that directly, and PT-141 half life explains why the 45-minute pre-dosing window exists in the first place.

Which one is right for which problem: low desire versus erectile dysfunction?

This sounds obvious once you say it plainly, but a surprising number of people reach for the wrong drug because the marketing around both blurs the line. If the problem is erections not happening or not lasting despite feeling interested, that's an erectile dysfunction problem, and sildenafil (or another PDE5 inhibitor) is the mechanism built for that. Vascular flow is the bottleneck; PT-141 doesn't fix a vascular bottleneck. If the problem is not wanting sex at all, feeling no pull toward it despite it mattering to you and causing distress, that's closer to what HSDD trials measured, and bremelanotide's central mechanism is aimed at that signal specifically ^[1][11]. A pill that improves blood flow won't manufacture desire that isn't there. Some people have both problems at once, which is exactly why HSDD and ED get conflated so often in ads. They're not the same diagnosis and the two drugs weren't built or tested to solve each other's problem.

Are there non-drug or lifestyle factors that affect how well either drug works?

Yes, and both drug classes get less effective when the underlying driver isn't pharmacological at all. A 2022 review on hypertension management and female sexual dysfunction found blood pressure medications themselves can suppress desire and arousal as a side effect, meaning the drug causing low libido might be sitting in the same medicine cabinet as the one meant to treat it ^[20]. A 2021 review on HSDD physiology and diagnosis emphasized that relationship context, stress, and other psychosocial factors are part of a full workup before medication is even considered appropriate ^[21]. For sildenafil, vascular risk factors, smoking, diabetes, and psychological performance anxiety all affect how well the drug performs, since it depends on an intact nerve and vessel pathway to work at all. Neither drug is a fix for a relationship problem, depression, or a medication side effect from something else you're taking. A 2022 review on pharmacotherapy for sexual dysfunction in women frames drug treatment as one tool among several, not a stand-alone answer ^[22].

What does PT-141 cost compared to Viagra, and is either covered by insurance?

Brand-name Vyleesi list pricing has historically run several hundred dollars per month depending on pharmacy and insurance formulary status, and insurance coverage for HSDD treatment is inconsistent; many plans require prior authorization or don't cover it at all, similar to how flibanserin (Addyi) coverage has been spotty. Generic sildenafil, by contrast, is inexpensive, often available for a fraction of brand Viagra's price once generics entered the market after Pfizer's patent expired. Compounded bremelanotide, sourced through a compounding pharmacy under 503A rules rather than as the FDA-approved Vyleesi product, is sometimes priced lower than brand Vyleesi, but it comes without the FDA review of a specific finished product's manufacturing consistency ^[18]. That's a genuine tradeoff to weigh, not a reason to assume compounded is automatically worse or automatically fine. If you're going the legitimate route for bremelanotide, working through a provider who reviews your history and prescribes appropriately, rather than buying from an unverified online source, is the difference between medical treatment and a gamble. Bremelanotide Rx works with providers who review candidates against the same criteria used in the Vyleesi trials, and fulfillment for prescribed treatment runs through a licensed pharmacy partner, not a generic online seller.

Frequently asked questions

Is PT-141 the same thing as female Viagra?

No, though it gets called that informally. PT-141 (bremelanotide, brand name Vyleesi) works on brain melanocortin receptors to affect desire, while Viagra works on blood vessels to improve erections. An early 2006 paper even used the phrase "female Viagra" to describe bremelanotide's early positioning, but the mechanisms are unrelated ^[17].

Can women take Viagra instead of PT-141?

Sildenafil is not FDA-approved for any female sexual dysfunction indication. Its vascular mechanism can increase genital blood flow, but low desire is a central nervous system issue, not primarily a blood flow issue, so it doesn't address the same problem bremelanotide targets ^[1][2].

Does PT-141 help with erections in men?

There's no FDA-approved PT-141 product for men. Older research explored bremelanotide for male erectile dysfunction, including in men who didn't respond to PDE5 inhibitors, but that never resulted in an approved male indication in the US ^[9].

Why does PT-141 cause nausea and Viagra usually doesn't?

Bremelanotide acts centrally on melanocortin receptors, and nausea is a known central effect of that pathway, reported in roughly 40% of trial participants, especially after the first dose ^[11][15]. Sildenafil's side effects come from peripheral vasodilation, producing headache and flushing rather than nausea as the leading complaint.

How fast does PT-141 work compared to Viagra?

Vyleesi is dosed at least 45 minutes before anticipated activity ^[6]. Sildenafil is typically taken 30 to 60 minutes beforehand. Both need a lead time; neither works instantly, and food or alcohol can slow sildenafil absorption further.

Is bremelanotide safe for people with high blood pressure?

Bremelanotide can cause a transient rise in blood pressure and a drop in heart rate after dosing, so it's not recommended for people with uncontrolled hypertension or known cardiovascular disease ^[16][20]. Anyone with blood pressure concerns should discuss this directly with a prescriber before starting.

Can PT-141 and Viagra be taken on the same day by the same person?

There's no approved combination protocol and no dedicated trial data on stacking them in one person. Because bremelanotide affects blood pressure and heart rate and sildenafil affects vascular tone, combining them without medical guidance isn't something to do on your own judgment.

How is PT-141 different from flibanserin (Addyi)?

Both target HSDD, but flibanserin is a daily oral pill affecting serotonin and dopamine pathways, while bremelanotide is an on-demand injection acting on melanocortin receptors ^[10][23]. A 2021 commentary questioned whether either drug's approval should be treated as strong precedent for the other given modest trial effect sizes ^[10].

Does PT-141 work for every woman with low libido?

No. The FDA approval covers a specific diagnosis, acquired generalized HSDD in premenopausal women, not low libido from any cause ^[3][6]. Trial data shows a modest average improvement over placebo, and some published re-analyses argue the effect size is smaller than headline results suggest ^[13][14].

Is compounded PT-141 as reliable as FDA-approved Vyleesi?

Compounded bremelanotide is sourced under 503A/503B bulk substance rules rather than approved as a finished product by the FDA, so it hasn't gone through the same manufacturing consistency review Vyleesi underwent ^[18][19]. That doesn't automatically make it unsafe, but it's a real regulatory difference worth understanding before choosing a source.

What's the difference in how long PT-141 and Viagra stay in your system?

Bremelanotide and sildenafil have different half-lives and different single-dose limits (Vyleesi is capped near 8 doses per month in its studied regimen) ^[6]. For the specific half-life figures and what they mean for re-dosing, see our dedicated half-life page rather than guessing from general pharmacology.

Can PT-141 cause weight loss the way some melanocortin drugs do?

Melanocortin receptor pathways are tied to appetite regulation as well as desire, and a phase 1 dataset in obese women found measurable body weight effects from bremelanotide dosing ^[5]. That's not the same as bremelanotide being a weight loss drug; it's a signal that the receptor system reaches beyond sexual response.

Sources

1. PubMed, Bremelanotide (2012 entry): Bremelanotide's action is centered on melanocortin pathways rather than vascular mechanisms.
2. CNS Spectrums, 2022, PMID 33455598: Describes the neurobiology of bremelanotide's central melanocortin action in premenopausal women with HSDD, distinct from peripheral vasoactive ED drugs.
3. Drugs, Bremelanotide: First Approval, 2019, PMID 31429064: Bremelanotide (Vyleesi) was FDA-approved in 2019 for acquired, generalized HSDD in premenopausal women.
4. Nature Reviews Endocrinology, 2023, PMID 37365323: Central melanocortin system, including MC4R, is a target studied for both metabolic and sexual pathways.
5. Diabetes, Obesity & Metabolism, 2022, PMID 35170192: Phase 1 data in obese women showed measurable body weight effects from bremelanotide dosing.
6. The Annals of Pharmacotherapy, 2020, PMID 31893927: Describes Vyleesi's approved subcutaneous dosing regimen and monthly dose limits.
7. Drugs@FDA, FDA-approved drug products database: Source for confirming original sildenafil (Viagra) FDA approval and subsequent generic approvals.
8. Current Topics in Medicinal Chemistry, 2007, PMID 17584134: Melanocortin-based compounds were studied for both male and female sexual dysfunction in earlier drug development.
9. PubMed, Bremelanotide (2006 entry), PMID 31369224: Early bremelanotide research explored use in male erectile dysfunction, including PDE5 inhibitor non-responders.
10. Drug and Therapeutics Bulletin, 2021, PMID 34642243: Commentary questions using bremelanotide and flibanserin's approvals as regulatory precedent for each other.
11. Obstetrics and Gynecology, 2019, PMID 31599840: RECONNECT phase 3 trials measured FSFI desire domain and FSDS-DAO change, with nausea reported in a large share of participants.
12. The Journal of Sexual Medicine, 2019, PMID 31277966: Phase 2b dose-ranging responder analysis found variable response rates depending on dose.
13. Journal of Sex Research, 2024, PMID 36809187: Re-examination of phase 3 data argues the clinically meaningful effect of bremelanotide over placebo is small.
14. Journal of Sex Research, 2021, PMID 33678061: Re-analysis of phase III trials raises concerns about how HSDD outcomes were defined and measured.
15. Journal of Women's Health, 2022, PMID 35147466: Pooled safety data across the bremelanotide development program shows nausea, flushing, and headache as most frequent adverse events.
16. Medical Letter on Drugs and Therapeutics, 2019, PMID 31381550: Bremelanotide can cause transient blood pressure increases and heart rate decreases, cautioning against use in uncontrolled hypertension.
17. Expert Review of Endocrinology & Metabolism, 2006, PMID 30290453: Early paper discusses bremelanotide under the informal framing of a 'female Viagra' concept.
18. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Compounded bremelanotide sourcing is governed by FDA's 503A bulk drug substance framework, separate from FDA-approved finished product review.
19. 21 CFR 216.24, the 503B Bulks List: 503B outsourcing facility bulk substance rules apply to compounded bremelanotide as an alternative sourcing pathway.
20. Medicina (Kaunas), 2022, PMID 35630054: Blood pressure medications can themselves suppress desire and arousal, complicating female sexual dysfunction treatment.
21. Journal of Midwifery & Women's Health, 2021, PMID 34510696: Full HSDD workup includes psychosocial and relationship context before medication is considered appropriate.
22. Current Psychiatry Reports, 2022, PMID 35102537: Frames pharmacotherapy for female sexual dysfunction as one tool among several, not a stand-alone solution.
23. Current Opinion in Obstetrics & Gynecology, 2022, PMID 36036468: Reviews pharmacologic options for sexual dysfunction including comparison of mechanisms across approved drugs.